Walleye Capital’s Deep Medicine Acquisition Corp. Rights DMAQR Stock Holding History

Walleye Capital’s Portfolio DMAQR Stock Details DMAQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-269,792	Closed	-$80.9K	–	6133
2023 Q4	$80.9K	Sell	269,792 -45,000	-14%	-$13.9K	﹤0.01%	4135
2023 Q3	$110K	Sell	314,792 -55,000	-15%	-$14.5K	﹤0.01%	3904
2023 Q2	$59.2K	Buy	369,792 +100,128	+37%	+$16.4K	﹤0.01%	3599
2023 Q1	$39.1K	Buy	269,664 +28,800	+12%	+$2.92K	﹤0.01%	3259
2022 Q4	$14.5K	Hold	240,864	–	–	﹤0.01%	2708
2022 Q3	$9K	Buy	240,864 +100,000	+71%	+$11.1K	﹤0.01%	2843
2022 Q2	$16K	Buy	140,864 +64	+0%	+$10	﹤0.01%	1939
2022 Q1	$25K	Hold	140,800	–	–	﹤0.01%	1924
2021 Q4	$45K	Buy	+140,800	New	+$44.5K	﹤0.01%	1788

Walleye Capital's DMAQR Position: Q1 2024 in Review

Walleye Capital sold out of Deep Medicine Acquisition Corp. Rights (DMAQR) in Q1 2024, closing a stake of 269,792 shares — an estimated $80.9K sold.

Walleye Capital first reported a position in DMAQR in Q4 2021 and held it in 9 quarters. The position peaked at $110K in Q3 2023. 0 funds tracked by Wall St. Rank hold DMAQR as of Q1 2024.

Walleye Capital reported no remaining Deep Medicine Acquisition Corp. Rights position as of Q1 2024 after selling out during the quarter.
Walleye Capital sold 269,792 Deep Medicine Acquisition Corp. Rights shares in Q1 2024, an estimated $80.9K.
Walleye Capital first reported a position in Deep Medicine Acquisition Corp. Rights in Q4 2021 and held it in 9 quarters.
Walleye Capital's Deep Medicine Acquisition Corp. Rights position peaked at $110K in Q3 2023.
0 funds tracked by Wall St. Rank held Deep Medicine Acquisition Corp. Rights as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.